Cosentyx (secukinumab) - Novartis
Cosentyx: 5-year data from P3 FUTURE 2 trial (NCT01752634) for psoriatic arthritis at ACR (November 8-13, 2019) (Novartis) - Apr 24, 2019 - Q1 2019 Results: 2-year data from P3 FUTURE 5 trial (NCT02404350) for psoriatic arthritis at EULAR (June 12- 15, 2019) 
P3 data
https://www.novartis.com/sites/www.novartis.com/files/q1-2019-ir-presentation.pdf
 
Apr 24, 2019
 
 
7a1cda12-66ec-45b7-9641-50c825c68049.jpg

d87bb2d5-9ce9-4603-9b64-fe0d4423d71b.jpg